H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on XOMA stock, giving a Buy rating on December 9.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Xoma’s strong position despite recent setbacks. The company’s extensive portfolio of partnered assets provides a significant buffer against individual project failures, such as the recent Phase 3 miss by Rezolute’s ersodetug for congenital hyperinsulinemia. This breadth of assets ensures a diversified revenue stream and reduces reliance on any single project.
Furthermore, Xoma’s financial health remains robust, with a strong cash position at the end of the third quarter of 2025, allowing it to pursue further strategic partnerships and deals. The company’s ability to generate revenue from approved and late-stage assets, alongside its innovative approach to securing non-dilutive cash inflows, supports the positive outlook. These factors collectively underpin Pantginis’s confidence in Xoma’s long-term growth potential, justifying the Buy rating.
In another report released on December 9, Lucid Capital also initiated coverage with a Buy rating on the stock with a $76.00 price target.